← Back to Clinical Trials
RecruitingNCT05539677

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionMalignant Solid Tumors
SponsorN.N. Petrov National Medical Research Center of Oncology
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,000
SexALL
Min Age1 Year
Max AgeN/A
Start Date1998-09
Completion2030-12

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

Eligibility Criteria

Inclusion Criteria: * Signed inform consent * Histolgically verified solid tumour * Receiving systemic therapy for neoplasm * Has archival tumour tissue * Provide biosamples with living tumour tissue or blood samples for immunologic assessment Exclusion Criteria: * Concurrent Lymphoprolipherative disorder * Patients after stem cell or bone marrow thansplantation * Incomplete informaton on previous cancer history or medical history * Patients with known primary immunodeficiency * Patients receiving immunosupressive therapy for concurrent illness * Pregnant patients

Related Trials